Smith & Nephew : Q3 review – Miss on top line and slight reduction of guidance due to China
>Q3 review – Miss on the top line due to headwind in China - Q3 2024 revenues of $ 1,412m (+4.1% y-o-y) were 1% below ODDO BHF/consensus. Underlying growth was 4.0% (vs 6.1%/5.5% expected). China was named as primary reason for the slower development. Excluding China, group growth would have been at 5.9%. Forex had a neutral impact. No bottom line is reported on a quarterly base.Sports medicine & ENT and Orthopaedics impacted by China - Sports medicin...Smith & Nephew is a global medical devices business operating in the markets for advanced surgical devices comprising orthopaedic reconstruction and trauma, sports medicine and advanced wound management. Co.'s advanced medical products and services include: Orthopaedic Reconstruction and Trauma (joint replacement systems for knees and hips and products to help repair broken bones); Advanced Wound Management (treatment and prevention products for hard-to-heal wounds); and Sports Medicine (implants and enabling technologies for minimally invasive repair of the joint).
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.